[The evaluation of the use of antineoplaston AS2-1 treatment in subacute sclerosing panencephalitis].
A follow-up study was carried out of 16 SSPE patients two years after completion of 6-month treatment with Antineoplaston. The study was based on an inquiry sent to the families of the patients and on control examinations at the clinic. In the period of follow-up 6 patients died, all had the downhill type of disease course and their mean survival was 18 months. Out of the remaining 10 patients 4 are in stationary condition and the remaining ones had minimal worsening. A more detailed clinical analysis showed that half the patients were in contact with and general orientation in the environment, but impairment of motor functions made difficult in most cases self-care and self-dependent functioning. All patients had evident changes in brain MRI. The survival time of the patients has been as yet from 2.5 to 5.5 years (mean 3.9 years). The results of the treatment with Antineoplaston AS2-1 + isoprinosine are comparable with those observed during isoprinosine alone treatment but significantly worse than those after administration of Propionibacterium granulosum with isoprinosine. This suggests that Antineoplaston AS2-1 fails to modify importantly the natural course of SSPE.
Sobczyk
W
W
I Kliniki Neurologicznej Instytutu Psychiatrii i Neurologii w Warszawie.
Piłkowska
E
E
Iwińska-Buksowicz
B
B
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D001921:Brain / Q000473:pathology; D018450:Disease Progression; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005973:Glutamine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007542:Inosine Pranobex / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008297:Male; D010648:Phenylacetates / Q000627:therapeutic use*; D013344:Subacute Sclerosing Panencephalitis / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D004338:Drug Combinations; D010648:Phenylacetates; D005973:Glutamine; C092038:antineoplaston AS 2-1; D007542:Inosine Pranobex